SynRx Therapeutics

Explore the latest insights on SynRx Therapeutics and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of SynRx Therapeutics’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

SynRx Therapeutics' SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status
CompanyDrug

SynRx Therapeutics’ SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status

SynRx Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to SYN818, the company's proprietary Polθ (DNA polymerase theta) inhibitor, in combination with…

Hisun Animal Health Receives MARA Approval for Telmisartan Oral Solution for Cats – Expanding Pet Pharmaceutical Portfolio in Chronic Kidney Disease Treatment

Hisun Animal Health Receives MARA Approval for Telmisartan Oral Solution for Cats – Expanding Pet Pharmaceutical Portfolio in Chronic Kidney Disease Treatment

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now